Click on the links below to read LongevityTechnology’s two-part interview with Greg Bailey, CEO of biopharmaceutical company Juvenescence, as he brings us up-to-speed on the company’s fundraise and his very busy year so far.

Part 1:  Transformative scientific opportunities, immuno-resilience, modifying aging and funding:  https://www.longevity.technology/juvenesence-1-from-strength-to-strength-in-rd-and-investment-firepower/

Part 2:  Democratising healthcare, paradigm shifts and disruptive technologies:  https://www.longevity.technology/juvenescence-2-its-all-about-prevention-and-thats-incredibly-disruptive/